Program
Leuprolide
Also written as “Leuprorelin”, “Leuprolide acetate” and “Leuprolide Acetate”.
Its studies are mostly in Prostatic Neoplasms · Puberty, Precocious · Alzheimer Disease · Endometriosis · Breast Neoplasms, led by 18 companies.
Drug pageLeuprolide: every studyMany companies study it; this page follows only the 38 they lead. All 153 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takedaits history only | 60 open or running | phase 4since Apr 23, 2015 | Oct 16, 2008 | none ahead |
| Abbottits history only | 50 open or running | phase 3since Feb 20, 2008 | Mar 20, 2003 | none ahead |
| AbbVieits history only | 30 open or running | phase 4since Jul 9, 2010 | Apr 24, 2008 | none ahead |
| Daewoong Pharmaceuticalits history only | 31 open or running | phase 4since Jul 3, 2012 | Jul 3, 2012 | none ahead |
| GP-Pharmits history only | 30 open or running | phase 3since Aug 8, 2005 | Aug 8, 2005 | none ahead |
| Astellas Pharmaits history only | 20 open or running | phase 4since Jan 25, 2017 | Sep 19, 2006 | none ahead |
| Chong Kun Dang Pharmaceuticalits history only | 20 open or running | phase 1since May 23, 2016 | May 23, 2016 | none ahead |
| Johnson & Johnsonits history only | 20 open or running | phase 2since Jun 17, 2009 | Jun 17, 2009 | none ahead |
| Oakwood Laboratoriesits history only | 20 open or running | phase 3since Jan 26, 2004 | Jan 26, 2004 | none ahead |
| Voyager Pharmaceuticalits history only | 20 open or running | phase 2since Jun 25, 2003 | Jun 25, 2003 | none ahead |
| bharat-serums-and-vaccines-limitedits history only | 10 open or running | phase 3since May 31, 2021 | May 31, 2021 | none ahead |
| dongkook-pharmaceutical-co-ltdits history only | 10 open or running | phase 3since Jun 13, 2024 | Jun 13, 2024 | none ahead |
| enteris-biopharma-incits history only | 10 open or running | phase 2since Oct 15, 2021 | Oct 15, 2021 | none ahead |
| Lee's Pharmaceuticalits history only | 10 open or running | no phasesince Aug 30, 2018 | Aug 30, 2018 | none ahead |
| LG Chemits history only | 11 open or running | phase 4since Jul 6, 2026 | Jul 6, 2026 | Aug 30, 2029phase 4 · NCT07710430 |
| peptron-incits history only | 10 open or running | phase 1since Mar 2, 2021 | Mar 2, 2021 | none ahead |
| tolmar-incits history only | 10 open or running | phase 3since May 5, 2015 | May 5, 2015 | none ahead |
| zodiac-produtos-farmaceuticos-s-aits history only | 10 open or running | phase 4since Mar 11, 2022 | Mar 11, 2022 | none ahead |
Also a collaborator on its studies: Parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 24 studies since Mar 20, 2003.
- May 5, 2015tolmar-inc’s first study: phase 3 study in Puberty, PrecociousNew to tolmar-inctolmar-inc · NCT02452931 · 64 enrolled · United States, Argentina, Canada and more
- May 23, 2016Chong Kun Dang Pharmaceutical’s first study: phase 1 study in Postmenopausal DisorderNew to Chong Kun Dang PharmaceuticalChong Kun Dang Pharmaceutical · NCT03233932 · 13 enrolled · Korea, Republic of
- Jan 12, 2017Phase 1 study in Prostatic NeoplasmsDaewoong Pharmaceutical · NCT03029533 · 44 enrolled
- Jan 25, 2017Phase 4 study in Prostatic NeoplasmsAstellas Pharma · NCT03035032 · 107 enrolled · Hong Kong, Indonesia, Malaysia and more
- Aug 30, 2018Lee's Pharmaceutical’s first study: no phase study in Prostatic NeoplasmsNew to Lee's PharmaceuticalLee's Pharmaceutical · NCT03662958 · 48 enrolled · China
- Oct 2, 2018Phase 3 study in Puberty, PrecociousAbbVie · NCT03695237 · 45 enrolled · United States, Puerto Rico
- Mar 2, 2021peptron-inc’s first study: phase 1 study in Prostatic NeoplasmsNew to peptron-incpeptron-inc · NCT04783636 · 40 enrolled
- Apr 8, 2021Phase 1 study in Puberty, PrecociousChong Kun Dang Pharmaceutical · NCT04840745 · 32 enrolled · Korea, Republic of
- May 31, 2021bharat-serums-and-vaccines-limited’s first study: phase 3 study in Advanced Prostate AdenocarcinomaNew to bharat-serums-and-vaccines-limitedbharat-serums-and-vaccines-limited · NCT04914195 · 155 enrolled · India
- Oct 15, 2021enteris-biopharma-inc’s first study: phase 2 study in EndometriosisNew to enteris-biopharma-incenteris-biopharma-inc · NCT05096065 · 16 enrolled · United States
- Mar 11, 2022zodiac-produtos-farmaceuticos-s-a’s first study: phase 4 study in Prostatic NeoplasmsNew to zodiac-produtos-farmaceuticos-s-azodiac-produtos-farmaceuticos-s-a · NCT05304169 · 48 enrolled · Brazil
- Aug 29, 2023Phase 3 study in Puberty, PrecociousDaewoong Pharmaceutical · NCT06025409 · 79 planned · Korea, Republic of
- Jun 13, 2024dongkook-pharmaceutical-co-ltd’s first study: phase 3 study in Advanced Prostate CancerNew to dongkook-pharmaceutical-co-ltddongkook-pharmaceutical-co-ltd · NCT06490328 · 161 enrolled · South Korea
- Jul 6, 2026LG Chem’s first study: phase 4 study in Puberty, PrecociousNew to LG ChemLG Chem · NCT07710430 · 43 planned · South Korea
Ahead
- Aug 30, 2029Primary completion: phase 4 study in Puberty, PrecociousLG Chem · NCT07710430
TargetBeta
“Gonadotropin-releasing hormone receptor agonist; Gonadotropin-releasing hormone receptor agonist”ChEMBL 37, by rule
Other programs on GNRHR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| triptorelinrule | Ipsen | phase 4 | 21 |
| Goserelinrule | AstraZeneca | phase 4 | 14 |
| linzagolixrule | Kissei Pharmaceutical | phase 3 | 14 |
| GnRH Antagonist SHR7280 | Jiangsu HengRui Medicine | phase 3 | 10 |
| Gonadotropin-Releasing Hormonerule | Ferring Pharmaceuticals | phase 3 | 5 |
| leuprolide mesylaterule | foresee-pharmaceuticals-co-ltd | phase 3 | 3 |
Studies
All 38 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07710430Puberty, Precocious · South Korea | 4 | Recruiting | LG Chem | Aug 30, 2029 | 43 |
| NCT06490328Advanced Prostate Cancer · South Korea | 3 | Completed | dongkook-pharmaceutical-co-ltd | Jan 21, 2026 | 161 |
| NCT06025409Puberty, Precocious · Korea, Republic of | 3 | Recruiting | Daewoong Pharmaceutical | Feb 28, 2025 | 79 |
| NCT05304169Prostatic Neoplasms · Brazil | 4 | Completed | zodiac-produtos-farmaceuticos-s-a | Jun 15, 2018 | 48 |
| NCT05096065Endometriosis · United States | 2 | UNKNOWN | enteris-biopharma-inc | May 2022 | 16 |
| NCT04914195Advanced Prostate Adenocarcinoma · India | 3 | Completed | bharat-serums-and-vaccines-limited | Sep 29, 2022 | 155 |
| NCT04840745Puberty, Precocious · Korea, Republic of | 1 | UNKNOWN | Chong Kun Dang Pharmaceutical | Oct 2021 | 32 |
| NCT04783636Prostatic Neoplasms | 1 | UNKNOWN | peptron-inc | Jul 20, 2021 | 40 |
| NCT03695237Puberty, Precocious · United States, Puerto Rico | 3 | Completed | AbbVie | May 6, 2021 | 45 |
| NCT03662958Prostatic Neoplasms · China | – | UNKNOWN | Lee's Pharmaceutical | Oct 2018 | 48 |
| NCT03035032Prostatic Neoplasms · Hong Kong, Indonesia, Malaysia and more | 4 | Completed | Astellas Pharma | Nov 19, 2019 | 107 |
| NCT03029533Prostatic Neoplasms | 1 | UNKNOWN | Daewoong Pharmaceutical | Nov 2017 | 44 |
| NCT03233932Postmenopausal Disorder · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Jul 2017 | 13 |
| NCT02452931Puberty, Precocious · United States, Argentina, Canada and more | 3 | Completed | tolmar-inc | Sep 5, 2018 | 64 |
| NCT02427958Puberty, Precocious · China | 4 | Completed | Takeda | Nov 23, 2018 | 307 |
| NCT02085252Prostatic Neoplasms · France | 3 | Completed | Takeda | Nov 8, 2016 | 116 |
| NCT01634321Puberty, Precocious · Korea, Republic of | 4 | Completed | Daewoong Pharmaceutical | Aug 2012 | 63 |
| NCT01546649Premenopausal Breast Cancer · Japan | 3 | Completed | Takeda | Dec 2014 | 167 |
| NCT01546623Prostatic Neoplasms · Japan | 3 | Completed | Takeda | Apr 2014 | 160 |
| NCT01415960Prostatic Neoplasms · United States | 3 | Completed | GP-Pharm | May 2013 | 163 |
| NCT01161563Prostatic Neoplasms · United States | 4 | Completed | AbbVie | Apr 2011 | 118 |
| NCT01088529Prostatic Neoplasms · United States | 2 | Completed | Johnson & Johnson | Mar 2013 | 66 |
| NCT00924469Prostatic Neoplasms · United States | 2 | Completed | Johnson & Johnson | Feb 2012 | 58 |
| NCT00817739Prostatic Neoplasms | 2 | Completed | Takeda | Sep 2005 | 341 |
| NCT00776074Leiomyoma | 2 | Completed | Takeda | Jul 2007 | 80 |
| NCT00667446Puberty, Precocious · United States, Puerto Rico | 3 | Completed | AbbVie | Oct 2012 | 72 |
| NCT00660010Puberty, Precocious · United States | 3 | Completed | Abbott | Apr 2009 | 55 |
| NCT00635817Puberty, Precocious · United States, Puerto Rico | 3 | Completed | Abbott | Jan 2010 | 84 |
| NCT00630799Prostatic Neoplasms · United States | 3 | Terminated | GP-Pharm | Apr 2009 | 20 |
| NCT00626431Prostatic Neoplasms · United States | 3 | Completed | Abbott | Aug 2009 | 310 |
| NCT00598312Prostatic Neoplasms · United States | 3 | Completed | Oakwood Laboratories | Aug 2008 | 201 |
| NCT00378690Prostatic Neoplasms · Belgium, Czech Republic, Finland and more | 3 | Completed | Astellas Pharma | Jun 2011 | 706 |
| NCT00275262Hodgkin Disease · United States | 2 | Terminated | Abbott | Feb 2009 | 25 |
| NCT00128531Prostatic Neoplasms · United States, Austria, Czech Republic and more | 3 | Completed | GP-Pharm | 120 | |
| NCT00076531Prostatic Neoplasms | 3 | Completed | Oakwood Laboratories | Nov 2004 | |
| NCT00076440Alzheimer Disease · United States | 2 | Completed | Voyager Pharmaceutical | Mar 2007 | 90 |
| NCT00063310Alzheimer Disease · United States | 2 | Completed | Voyager Pharmaceutical | Feb 2006 | 90 |
| NCT00056654Prostatic Neoplasms · United States | – | Completed | Abbott | Jul 2004 | 164 |
How it is read
Names in the registry
- “Leuprorelin”, 4 entries
- “Leuprolide acetate”, 4 entries
- “Leuprolide”, 2 entries
- “Leuprolide Acetate”, 2 entries
- “TAP-144-SR(6M)”, 2 entries
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 21 studies
- Puberty, Precocious, 10 studies
- Alzheimer Disease, 2 studies
- Endometriosis, 1 study
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.